Advertisement
Canada markets closed

  • S&P/TSX

    21,642.87
    -97.33 (-0.45%)
     

  • S&P 500

    5,051.41
    -10.41 (-0.21%)
     

  • DOW

    37,798.97
    +63.86 (+0.17%)
     

  • CAD/USD

    0.7233
    -0.0020 (-0.28%)
     

  • CRUDE OIL

    85.33
    -0.03 (-0.04%)
     

  • Bitcoin CAD

    88,164.40
    +748.13 (+0.86%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,401.50
    -6.30 (-0.26%)
     

  • RUSSELL 2000

    1,967.48
    -8.23 (-0.42%)
     

  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     

  • NASDAQ futures

    17,900.00
    +18.75 (+0.10%)
     

  • VOLATILITY

    18.40
    -0.83 (-4.32%)
     

  • FTSE

    7,820.36
    -145.17 (-1.82%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6810
    -0.0014 (-0.21%)
     
BREAKING:

$535B CANADA BUDGET PROJECTS $39.8B DEFICIT, AIMS TO RESTORE ECONOMIC FAIRNESS

It seeks to ease the housing and affordability crisis by making older, wealthier Canadians pay more

COVID-19 vaccine developer CureVac plans 5 million share sale

Reuters
·1 min read

Jan 25 (Reuters) - German biotech firm CureVac plans to sell 5 million shares in a secondary offering, the company said on Monday, as it starts late-stage trials of its COVID-19 vaccine candidate.

The proceeds will be used to fund its messenger RNA-vaccine program and expand its in-house manufacturing capacities, the company said.

Earlier this month, CureVac struck an alliance with drugmaker Bayer AG to help develop its experimental COVID-19 vaccine.

CureVac's shares fell 3.3% to $101.01 in extended trading on Monday.

The Nasdaq-listed company, which is backed by investors Dietmar Hopp, the Gates Foundation and GlaxoSmithKline as well as the German government, has said it aims to produce up to 300 million doses of the vaccine in 2021 and up to 600 million in 2022. (Reporting by Munsif Vengattil in Bengaluru; Editing by Sriraj Kalluvila)